Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|November 13, 2017

Pfizer Appoints New COO

The company has appointed Albert Bourla, PhD, as its new COO.

Pfizer announced on Nov. 13, 2017 that it appointed Albert Bourla, PhD, as its new COO, effective Jan. 1, 2018.

Since early 2016, Dr. Bourla has been the group president of Pfizer’s innovative health business, and has held a range of senior global positions. He holds a PhD degree in the biotechnology of reproduction from the Veterinary School of Aristotle University.

“The naming of a chief operating officer comes at a time when our business is strong as we continue to advance our strategy while also managing a dynamic and challenging external environment, said Ian Read, Pfizer chairman and CEO.

Source: Pfizer


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.